

IBM Micromedex

Shou Ray Information Service
2021

大綱

Micromedex 內容簡介



Micromedex 使用介面



在 Micromedex 中查找藥物資訊




Ask Watson – 有問題，問華生！

Micromedex 內容簡介

Micromedex 收錄內容範圍

Micromedex® Solutions Healthcare Series



內容特性

◆ Authority 權威性

- ◆ DrugDex, Poisindex, DiseaseDex Emergency Medicine was adapted by U.S, Department of State as official medical encyclopedia

◆ Quality 高品質

- ◆ Strict editorial process

◆ Reliability 專業可靠

- ◆ Provide service for schools, hospitals , and pharmaceutical companies over 30 years

◆ Consistency 一致性

- ◆ Consistency formats and standards

◆ Full-text databases 全文閱讀

- ◆ Fully referenced, Peer reviewed, Written by clinicians

資料來源

Drug Information	Disease Information
DRUGDEX [®] System	DISEASEDEX [™] General Medicine
DRUG-REAX [®] System	DISEASEDEX [™] Emergency Med.
MARTINDALE	Lab adviser [™]
Index Nominum	Patient Education
Physicians' Desk	AltCareDex [®] Alternative Medicine
Reference [®] (PDR [®])	Education
P & T QUIK [®] Reports	CareNotes [™] System
IV INDEX [®] System	Toxicology Information
MSDS from USP	POISINDEX [®] System
IDENTIDEX [®] System	TOMES [®] System
Red Book [®] Online	REPRORISK [®] System
KINETIDEX [®] System	
Alternative Medicine	Free Resources
AltMedDex [®] System	Calculators
AltMedDex [®] Protocols	Micromedex Apps

Micromedex 使用介面

主頁

藥物
相互作用

IV 相容性

藥物
鑒定藥物
比較

CareNotes

NeoFax® /
Pediatrics

其他工具 ▼

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

Keyword search



1 檢索區

Ask Watson

Search Micromedex drug information

Type a quick question...

[Learn more](#) ?

最新消息

4

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

Read Top News



支援和訓練

5

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

Support Request



資源

6

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

資料庫登入方式

- IP認證機制
 - 在IP範圍內，從單位圖書館網頁連結
 - 利用校 / 院外連線設定Proxy或VPN
 - 有同時上線人數限制 養成好習慣，用完要登出
- 行動載具APP 訂戶專屬
 - 每次登入會自動更新資料
 - 可離線使用，不受網路死角影響

資料庫使用方式

機構IP範圍內

需有網路連線

上線人數限制

完整全文內容

行動載具APP

無需網路連線

無人數限制

僅有簡要解答

APP下載



可離線使用，不受制於使用人數

APP使用方式



IBM mobileMicromedex®

Put the power of Micromedex on your mobile device

Accessing IBM Micromedex with Watson for Mobile Browsers

Accessing IBM Micromedex with Watson

Micromedex Apps on Mobile Devices



- The **IBM Micromedex Drug Int.** app for Apple, and Android devices is available for FREE for Micromedex subscribers.
- You can access these apps via the App Store (Apple devices) or Google Play® (Android devices).
- You can activate the app by following the simple instructions below.

Simple instructions for installation:

- Step 1:** Visit the App Store from your device and search IBM Micromedex Drug Int.
- Step 2:** From the App, select download / install the application. You may be prompted to enter your Apple or Google ID.
- Step 3:** The app will download to your app library, or directly to your device.
- Step 4:** Open the app. Enter the password begin using **IBM Micromedex Drug Int.** The password is case-sensitive. Please enter it exactly as it appears here.

IBM Micromedex IV Comp.

This app is free only for clinicians ("subscribers") who work at a hospital or facility with an online subscription to IBM Micromedex®. Subscribers can obtain their password by signing into Micromedex and following the "Download Center" link at the top of the page - or by simply contacting our Support Center.

The password only needs to be entered once per year.

Need Help? Not sure if you work at a hospital or facility that subscribes to Micromedex? Can't find the link to the password? Visit Our Support Center.

www.micromedex.com/mobile

Once you've obtained your password, please enter it below:

APP Password

Continue

Please provide a password to continue.

Interactions

aspi

✕

Drug List


Selected Drugs


Aspirin	✓
Aspirin/Butalbital/Caffeine	+
Aspirin/Caffeine/Dihydrocodeine Bitartrate	+
Aspirin/Codeine Phosphate	+
Aspirin/Dipyridamole	+
Aspirin/Omeprazole	+
Aspirin/Oxycodone Hydrochloride	+
Aspirin/Pravastatin Sodium	+
Aspirin (Aspirin)	+
Aggrenox (Aspirin/Dipyridamole)	+
Anacin Aspirin Free (Acetaminophen)	+
Ascomp w/Codeine (Butalbital/Aspirin/Caffeine/Codeine Phosphate)	+

Interactions

Drug List

Selected Drugs

 Warfarin Sodium

 Aspirin

Clear All

View Interactions

Interactions

✓ Major

S

Warfarin Sodium : Aspirin

Interactions

Warfarin Sodium : Aspirin

Severity: Major

Onset: Not Specified

Documentation: Fair

Interaction Effect:

Concurrent use of WARFARIN and ANTIPLATELET AGENTS may result in increased risk of bleeding.


Clinical Management:

Coadministration of warfarin and antiplatelet agents may increase the risk of bleeding. Monitor patients closely for signs or symptoms of bleeding (Prod Info Jantoven(R) oral tablets, 2014) and evaluate promptly. Lab monitoring may be appropriate.

Probable Mechanism:
additive effects

APP小提醒

- 只有**簡要解答 (Summary)**
 - 深入解答仍需回到Micromedex網頁查詢
- 密碼到期
 - 新密碼的取得須在**IP範圍內登入**Micromedex 資料庫，進入 **下載中心** 頁面或  **Download Mobile Apps** 即可找到。



我的訂閱

[主頁](#)

IV 相容性

藥物比較

CareNotes

其他工具 ▼

搜尋藥物

已經訂購


尚未訂購

tson

romedex drug information

on...

→

Learn more 

Your Subscribed Products

Non-subscribed Products

MICROMEDEX

MICROMEDEX


 AAPCC Codes in POISINDEX®

 Alternative Medicine

 Detailed Drug Information for the Consumer


 DISEASEDEX™ Emergency Medicine

 DISEASEDEX™ General Medicine


 [Imprint Codes in Identidex®](#)

 [Index Nominum](#)

 Interaction Checking

 Italian Drug Database

IV Compatibility

 Lab Advisor™ MARTINDALE

 MSDS from USP

PharmacyXpert

列印 關閉

- _____
- _____
- _____






資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS





Download Mobile Apps


















Your Subscribed Products**MICROMEDEX**

-  Alternative Medicine
-  DRUGDEX® System
-  Imprint Codes in Identidex®
-  Interaction Checking
-  IV Compatibility

補充用藥：

-  Calculators
-  mobileMicromedex





外部應用：**Non-subscribed Products****MICROMEDEX**

-  AAPCC Codes in POISINDEX®
-  Detailed Drug Information for the Consumer
-  DISEASEDEX™ Emergency Medicine
-  DISEASEDEX™ General Medicine
-  Index Nominum
-  Italian Drug Database
-  Lab Advisor™
-  MARTINDALE
-  MSDS from USP
-  P&T QUIK® Reports
-  PDR®
-  POISINDEX® Managements
-  POISINDEX® System
-  RED BOOK Online®
-  REPRORISK® System
-  TOMES® System
-  United Kingdom Drug Information

補充用藥：

N/A

外部應用：

-  CareNotes®
-  Formulary Advisor®
-  NeoFax®
-  Pediatrics

Training Center

最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrovelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

Read Top News



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

IBM Micromedex®

Click the **Header** (blue bar) to view the list of courses | Then click the **Title** link for a description of the course

^ Quick Tips

^ Overviews

^ Tools & Apps

^ Micromedex in Your Workflow

^ Toxicology

^ International

^ Guides

- IBM ActionOI®
 - IBM ActionOI Practice Insights®
- IBM CareDiscovery®
- IBM CareDiscovery® Electronic Quality Measures
- IBM CareDiscovery® Quality Measures
- IBM Market Expert®
- IBM Market Expert® State Data Scope
- IBM Micromedex® Clinical Knowledge
 - IBM Micromedex®
 - IBM Micromedex® (Integrated)
 - IBM Micromedex® NeoFax® and Pediatrics
 - IBM Micromedex® Pharmaceutical Knowledge
 - IBM Micromedex® RED BOOK®
 - IBM Micromedex® Formulary
- IBM Micromedex® Patient Connect
 - IBM Micromedex® CareNotes®
 - IBM Micromedex® CareNotes® (Integrated)

IBM Micromedex®

[我的訂閱](#) | [問道](#) | [Training Center](#) | [說明](#) | [下載中心](#) | [登出](#)





最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List



Latest News

關閉 X

Read Top News

▼ Caplyta(R) for Schizophrenia

On December 23, 2019, the US FDA approved Caplyta(R) (lumateperone) oral capsules indicated for the treatment of schizophrenia in adult patients. Caplyta demonstrated efficacy with a significantly improved Positive and Negative Syndrome Scale total score compared with placebo in 2 clinical trials. Caplyta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and is not approved for this indication.

The prescribing information can be found at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf.

The monograph for lumateperone can be found at:
<http://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?source=deepLink&SearchTerm=lumateperone>.

Last modified: 01/03/2020 11:40:24

Full Article

► Lynparza(R) Now for Pancreatic Cancer

► Ubrelvy(TM) to Treat Migraine

► Dayvigo(TM): Insomnia Treatment

► Enhertu(R) for HER2+ Breast Cancer

引用 Micromedex

最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

支援和訓練

- **Citing Micromedex**
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

HOW TO REFERENCE THE Truven Health Analytics SYSTEMS

Read Top News

[Top of page](#)

PLEASE NOTE: When referencing a Micromedex product or database, you *must* include: (electronic version), Truven Health Analytics information, URL address (<http://www.micromedexsolutions.com/>) and the date accessed.

Subscribers to the Licensed Solutions often ask how to reference the databases when publishing articles. The following formats should be used:

The entire Micromedex System:

[Top of page](#)

Micromedex® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

An entire System or Database:

[Top of page](#)

IBM Micromedex® Alternative Medicine:

IBM Micromedex® Alternative Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

CareNotes®:

CareNotes® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

IBM Micromedex® Disease Emergency Medicine:

IBM Micromedex® Disease - Emergency Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

IBM Micromedex® Disease General Medicine:

IBM Micromedex® Disease - General Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

常用資源 RESOURCES



最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

Read Top News



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

黑框警告

以藥物首字母序條列有黑框警告的藥物
意即研究表明該藥物具有嚴重的甚至危及生命的不良反應風險，是美國食品藥品監督管理局（FDA）對上市藥物採取的最嚴厲警告形式

跳轉到： A B C D E F G H I J K L M N **O** P Q R S T U V W X Y Z 0-9

顯示 30 of 999 條結果，帶有黑框警告

Obeticholic Acid

Obiltoximab

Obinutuzumab

Ofatumumab

Ofloxacin

Olanzapine

Olanzapine Pamoate

Ofloxacin

Drug Classes: [Antibacterial](#) | [Antibiotic](#) | [All](#)Routes: [Ophthalmic](#) | [Oral](#) | [Otic](#)

Regulatory Authority



FDA

簡要解答

深入解答

全部結果

Dosing/Administration

[Adult Dosing](#)[Pediatric Dosing](#)[FDA Uses](#)[Non-FDA Uses](#)[Dose Adjustments](#)[Administration](#)[Comparative Efficacy](#)[Place In Therapy](#)

Medication Safety

[Contraindications](#)[Precautions](#)[Adverse Effects](#)[Black Box Warning](#)

Medication Safety

Black Box Warning



請參閱 '深入解答' 瞭解詳細結果。

Oral (Tablet)

- Fluoroquinolones, including ofloxacin, are associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ofloxacin and avoid use of fluoroquinolones in patients with these serious adverse reactions. Reserve use of ofloxacin for patients with no alternative treatment options for acute exacerbation of chronic bronchitis or uncomplicated cystitis. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis [2].

相關結果

[替代藥物](#)[毒理學](#)[疾病](#)[Drug Consults](#)[Index Nominum](#)[Martindale](#)[PDR®](#)[Product Lookup - Martindale](#)[Product Lookup - RED Book](#)[Product Lookup - Tox & Drug](#)[消費者藥物資訊](#)

Ask Watson

Dosage

Class

► BENZODIAZEPINES (SELECTED)

► CORTICOSTEROIDS (SELECTED) PROPERTIES AND POTENCIES

► NSAID (NONSTEROIDAL ANTIINFLAMMATORY AGENTS (SELECTED))

Oral NSAIDs

Generic Name	Brand Name (US)	Indications	Effective Dosage Range
Diclofenac	Cataflam (diclofenac potassium immediate-release tablets)	Pain	50 mg 3 times daily
		Dysmenorrhea	50 mg 3 times daily
		Osteoarthritis	50 mg 2 to 3 times daily
		Rheumatoid Arthritis	50 mg 3 to 4 times daily
	Voltaren (diclofenac sodium enteric-coated tablets)	Ankylosing Spondylitis	25 mg 4 times daily, with an extra 25 mg at bedtime if needed
		Osteoarthritis, Rheumatoid Arthritis	50 mg 2 to 3 times daily, or 75 mg twice daily
	Voltaren XR (diclofenac sodium extended-release tablets)	Osteoarthritis	100 mg every day
		Rheumatoid Arthritis	75 to 100 mg once or twice daily

Comparative Tables

針對各廠牌藥品的降血糖藥，列出常用劑量範圍、最大劑量、低血糖風險、重量變化、胃腸症狀

Dosage

Class

▶ ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS (SELECTED)

▶ ANTIDIABETIC AGENTS (SELECTED)

▶ BETA BLOCKERS

Generic Drug Name And Brand Name	Usual Dosage Range*	Maximum Daily Dose	Drug Class	Hypoglycemia Risk**	Weight Change**	GI Symptoms**
Acarbose (Precose(R))	25 to 100 mg ORALLY 3 times daily with meals	60 kg or less: 150 mg; Greater than 60 kg: 300 mg	AGI	not significant	not significant	diarrhea, flatulence
Alogliptin (Nesina(R))	25 mg ORALLY once daily	---	DPP-4 inhibitor	not significant	not significant	not significant
Alogliptin Benzoate/Metformin (Kazano)	alogliptin 12.5 mg/metformin 500 mg to alogliptin 12.5 mg/metformin 1000 mg ORALLY twice daily with meals	alogliptin 25 mg/metformin 2000 mg	DPP-4 inhibitor /Biguanide	***	***	***
Alogliptin/Pioglitazone(Oseni)	alogliptin 25 mg/pioglitazone 15 mg to alogliptin 25 mg/pioglitazone 45 mg ORALLY once daily	alogliptin 25 mg/pioglitazone 45 mg	DPP-4 inhibitor/ TZD	***	***	***

Drug Consults

跳轉到： [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

顯示 55 of 628 藥物諮詢文章

[Abbreviations](#)

[Abuse-Deterrent Opioid Medications](#)


[ABVD - Used for Hodgkin's Disease](#)

[AC - Used for Breast Cancer](#)

[AC FOLLOWED BY T WITH TRASTUZUMAB](#)

治療霍奇金氏淋巴瘤的藥物

ABVD - Used for Hodgkin's Disease

藥物諮詢 

RESPONSE

- DOXOrubicin 25 mg/m(2) IV, days 1 and 15
- Bleomycin 10 mg/m(2) IV, days 1 and 15
- VinBLASTine 6 mg/m(2) IV, days 1 and 15
- Dacarbazine 375 mg/m(2) IV, days 1 and 15 [1]
- Repeat cycle every 28 days

Reference

1. Bonadonna G & Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9(1):21-35.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

Last Modified: February 06, 2017

REMS (Risk Evaluation & Mitigation Strategy)

跳轉到： [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

Displaying 3 of 78 results for "REMS"

Fentanyl

類鴉片止痛劑

Elements to Assure Safe Use, Implementation System, Medication Guide

Fentanyl Citrate

Fingolimod Hydrochloride

Fentanyl

Drug Classes: [Analgesic](#) | [Central Nervous System Agent](#) | [All](#)

Routes: [Sublingual](#) | [Transdermal](#)

簡要解答

深入解答

全部結果

連結到藥品安全訊息和用藥指南

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Medication Safety

REMS

 列印

Summary

- to reduce serious adverse outcomes (eg, addiction, unintentional overdose, death) resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications
- to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: prescribing and dispensing transmucosal immediate release fentanyl medicines only to appropriate patients, which includes use only in opioid-tolerant patients; preventing inappropriate conversion between transmucosal immediate release fentanyl medicines; preventing accidental exposure to children and others for whom it was not prescribed

Home

Drug
Interactions

IV Compatibility

Drug ID

Drug
Comparison

CareNotes

NeoFax / Pediatrics

Other Tools ▼

Fentanyl

Drug Classes: [Analgesic](#) | [Central Nervous System Agent](#) | [All](#)Routes: [Sublingual](#) | [Transdermal](#)

1.減少不良的後果(成癮、無心過量、死亡)
2.減輕誤用、濫用、過量、成癮的風險

Substance

Fentanyl ▼

Quick Answers

In-Depth Answers

All Results

Dosing/Administration

[Adult Dosing](#)[Pediatric Dosing](#)[FDA Uses](#)[Non-FDA Uses](#)[Dose Adjustments](#)[Administration](#)[Comparative Efficacy](#)[Place In Therapy](#)

Medication Safety

[Contraindications](#)[Precautions](#)[Adverse Effects](#)[Black Box Warning](#)[REMS](#)[Drug Interactions \(single\)](#)[IV Compatibility \(single\)](#)[Pregnancy & Lactation](#)[Monitoring](#)[Do Not Confuse](#)

Medication Safety

REMS

 Print

Summary

- To reduce serious adverse outcomes (eg, addiction, unintentional overdose, death) resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications
- To mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: prescribing and dispensing transmucosal immediate release fentanyl medicines only to appropriate patients, which includes use only in opioid-tolerant patients; preventing inappropriate conversion between transmucosal immediate release fentanyl medicines; preventing accidental exposure to children and others for whom it was not prescribed
- To educate prescribers, pharmacists, and patients on the potential for misuse, abuse, addiction, and overdose of transmucosal immediate release fentanyl medicines
- To inform patients or caregivers about the serious risks associated with transmucosal immediate release and extended-release or long-acting fentanyl treatment

REMS Components

- Medication Guide
- Elements to Assure Safe Use
- Implementation System

Drug Safety Information

- Duragesic(R)
https://www.accessdata.fda.gov/drugsatfda_docs/remis/ERLA_2017-05-26_REMS_Document.pdf
- Ionsys(R)
https://www.accessdata.fda.gov/drugsatfda_docs/remis/ionsys_2017-03-29_REMS_Document.pdf

Related Results

[Disease](#)
[Toxicology](#)[Consumer Drug Information](#)
[Drug Consults](#)
[Index Nominum](#)
[IT- Dialogo Sui Farmaci](#)
[Martindale](#)
[PDR®](#)
[Product Lookup - Martindale](#)
[Product Lookup - RED Book](#)
[Product Lookup - Tox & Drug](#)

查找藥物資訊

可輸入成份或是商品名稱

常見藥品諮詢問題種類

- 劑量(肝腎功能不良、老人、兒童)之調整及投藥方式
- 藥物不良反應
- 藥品交互作用
- 藥物動力學
- 適應症
- 中毒或藥品過量的處理
- 其他，
如：相容性、禁忌、費用、配製、安定性、貯存等

藥師綜合個案的問題

- 醫生考慮

一位75歲有心房顫動合併高血壓的病人，應該使用抗凝血藥物預防中風嗎？

- 病人需求

本人表示之前曾使用過Aspirin，但覺得吃了胃不舒服，所以不太喜歡...

- 家屬關心

擔心使用抗凝血藥物預防中風，是否會增加出血風險？

資料來源：新光吳火獅紀念醫院 劉人瑋藥師

利用Micromedex尋求支持的證據

IBM Micromedex®

我的訂閱 | 開道 | Training Center | 說明 | 下載中心 | 登出

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes

NeoFax / Pediatrics

其他工具 ▾

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

aspirin



Aspirin

Dosing Aspirin

Adverse Effects Aspirin

Indications Aspirin

Interactions Aspirin

Aspirin (Buffered)

Dosing Aspirin (Buffered)

Adverse Effects Aspirin (Buffered)

Ask Watson

Search Micromedex drug information

Type a quick question...



Learn more ?

支援和訓練

Micromedex

Consulting & Services

Content Options for MU & More

- Product User Tips & Quick Answers
- Training Center
- User Guide

Read Top News



Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

主頁	藥物 相互作用	IV 相容性	藥物 鑒定	藥物 比較	CareNotes®	NeoFax® / Pediatrics	其他工具 ▼
----	------------	--------	----------	----------	------------	----------------------	--------

關於以下項的搜尋 "WARFRIN" 與任何文件均不相符。

您要尋找的是不是：[afrin](#), [war-far-](#)**warfarin**, [en](#), [warthin](#)

Aspirin- Uses

Aspirin

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

Regulatory Authority



FDA



簡要解答

深入解答

全部結果

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

REMS

Drug Interactions
(single)

IV Compatibility (single)

Dosing/Administration

Non-FDA Uses



請參閱 [‘深入解答’](#) 瞭解詳細結果。

列印

- Adenocarcinoma of esophagus; Prophylaxis
- Atrial fibrillation - Thromboembolic disorder; Prophylaxis
- Cancer - Thromboembolic disorder; Prophylaxis
- Carotid artery stenosis
- Colorectal cancer, Nonmetastatic, post diagnosis
- Colorectal cancer; Prophylaxis
- Coronary stent stenosis, Subacute; Prophylaxis
- Death, Primary prevention in women
- Disorder of cardiovascular system, Secondary Prophylaxis
- Flushing, Niacin Induced
- In vitro fertilization - Pregnancy-induced hypertension; Prophylaxis

相關結果

替代藥物

毒理學

疾病

[Drug Consults](#)

[Index Nominum](#)

[Martindale](#)

[P&T QUIK 報告](#)

[PDR®](#)

[Product Lookup - Martindale](#)

[Product Lookup - RED Book](#)

[Product Lookup - Tox & Drug](#)

[消費者藥物資訊](#)

Ask Watson

Aspirin- Comparative Efficacy

考量問題：是否有其他藥物可選擇？

ASPIRIN

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

Regulatory Authority



FDA

簡要解答

深入解答

全部結果

Atrial fibrillation - Thromboembolism -- Comparative Efficacy

1 / 4 results 用於 atrial fibrillation - thromboembolic disorder; ...

Adult Dosing

Normal Dosage

Important Note

Beers Criteria: Use ca

Oral route

Atrial fibrillation - Throm

a) Guidelines from The

antithrombotic therapy

b) Patient With Atrial F

1) Guidelines from

Patients with a

placement, follo

ASPIRIN

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

簡要解答 | 深入解答 | 全部結果

Atrial fibrillation - Thromboembolism -- Comparative Efficacy

4 / 4 results 用於 atrial fibrillation - thromboembolic disorder; ...

Prior stroke and abnormal LV ejection fraction were significant prognostic risk factors for the development of stroke [1179].

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

a) The second Stroke Prevention in Atrial Fibrillation (SPAF-II) study demonstrated an increase in stroke rate in older compared to younger patients regardless of warfarin or aspirin therapy for non-rheumatic atrial fibrillation. Patients received dose-adjusted warfarin (INR 2.0 to 4.5) or aspirin 325 mg daily. Primary events were defined as ischemic stroke and systemic embolism. In patients 75 years or less (n=715) the rate of primary events in the aspirin group were 1.9% per year compared to 1.3% in the warfarin group (p=0.24). In patients older than 75 years (n=385) the rate of primary events in the aspirin group were 4.8% per year compared to 3.6% per year in the warfarin group (p=0.39). Patients (older than 75) in both the warfarin and aspirin group had similar stroke rates per year with residual deficit (hemorrhagic and ischemic), 4.6% and 4.3% respectively. With regard to all patients (ages combined), annual primary events were lower in the warfarin versus aspirin-treated group (1.9% and 2.7%, respectively; p=0.15). Selecting safe antithrombotic therapy for atrial fibrillation in older patients remains a challenge [1180].

b) Warfarin was superior to aspirin in preventing thromboembolic complications and vascular deaths in chronic, non-rheumatic atrial fibrillation in a controlled study involving 1007 outpatients. In this study, warfarin was given in an open fashion, with the aspirin and placebo arms being double-blind. Warfarin was given in doses to achieve a therapeutic range of 4.2 to 2.8 INR (international normalized ratio); aspirin was given as 75 mg once daily. Anticoagulation with warfarin should be considered in patients with chronic atrial fibrillation as long as contraindications are not present. In a follow-up report of the subjects in this study who received placebo, thromboembolic complications occurred significantly more frequently in those that had a previous myocardial infarction [1181][1182].

c) BAATAF (Boston Area Anticoagulation Trial for Atrial Fibrillation) Study: Warfarin was superior to aspirin for prevention of stroke in patients with nonrheumatic atrial fibrillation. In this study, the annual stroke rate was 0.45% among warfarin users compared to 3.9% among aspirin users and 1.8% among untreated patients. After controlling for various risk factors, the relative stroke rate with warfarin over that of aspirin was 0.029 to 0.64). The relative stroke rate of warfarin over that of untreated patients was also low, however, the 95% CI was extremely wide and included unity, probably as a result of insufficient power of the study.

Atrial fibrillation - Thrombosis; Prophylaxis

b) Warfarin was superior to aspirin in preventing thromboembolic complications and vascular deaths in chronic, non-rheumatic atrial fibrillation in a controlled study involving 1007 outpatients. In this study, warfarin was given in an open fashion, with the aspirin and placebo arms being double-blind.

Warfarin- FDA Uses

1. 考量問題：此藥物的適應症為何？

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------


WARFARIN

[Your search: Warfarin]

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: [Intravenous](#) | [Oral](#)

Regulatory Authority



FDA ▼

Quick Answers	In-Depth Answers	All Results
---------------	-------------------------	-------------

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses**
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Dosing/Administration

FDA Uses

See 'Quick Answers' for summary results.

Warfarin Sodium

- [Atrial fibrillation - Thromboembolic disorder](#)
- [Atrial fibrillation - Thromboembolic disorder; Prophylaxis](#)
- [Myocardial reinfarction; Prophylaxis](#)
- [Prosthetic cardiac valve component embolism](#)
- [Prosthetic cardiac valve component embolism; Prophylaxis](#)
- [Pulmonary embolism](#)
- [Pulmonary embolism; Prophylaxis](#)
- [Thrombosis, Post myocardial infarction; Prophylaxis](#)
- [Venous thromboembolism](#)
- [Venous thromboembolism; Prophylaxis](#)

Atrial fibrillation - Thromboembolic disorder

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

[View Full Document](#)

[Print](#)

Related Results

- [Disease](#)
- [Toxicology](#)
- [Consumer Drug Information](#)
- [Drug Consults](#)
- [Index Nominum](#)
- [IT- Dialogo Sui Farmaci](#)
- [Martindale](#)
- [PDR®](#)
- [Product Lookup - Martindale](#)
- [Product Lookup - RED Book](#)
- [Product Lookup - Tox & Drug](#)

FDA Uses

IBM Micromedex®

My Subscription | Gateway | Training Center | Help | Download Center | Logout

Warfarin



Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

See Drug Consult reference: [Atrial Fibrillation - Drug Treatment Guidelines](#)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

Strength of Evidence: Adult, Category A

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

b) Summary:

Product Availability

The marketing and distribution of warfarin sodium for injection has been discontinued as of 5/2/2014 [8]

Indication

Warfarin is indicated for the prophylaxis and treatment of thromboembolic complications as a result of atrial fibrillation (AF) [9]

Evidence (Nonvalvular Atrial Fibrillation)

Direct thrombin inhibitors (DTIs) were similar to adjusted-dose warfarin (INR target, 2 to 3) for reduction in the composite of vascular deaths and ischemic events or composite of stroke, systemic embolic event, MI, and cardiovascular mortality in patients with nonvalvular AF who had 1 or more risk factors for stroke in a meta analysis, and a randomized study of patients underlying electrical cardioversion [10][11]. No significant bleeding differences were observed between warfarin and edoxaban [11]; however, the addition of aspirin to oral anticoagulants significantly increased risk of major bleeding events and hospitalizations related to bleeding [12].

Evidence (Special Populations)


Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [13]; however, use of warfarin did not significantly lower the risk of stroke compared with no warfarin use in a metaanalysis of dialysis patients with AF [14]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [13], while warfarin use increased the bleed risk in dialysis patients [14].

是否為核准的適應症用藥？
有建議強度與證據等級嗎？



檢視證據等級與建議強度

RECOMMENDATION, EVIDENCE AND EFFICACY RATINGS

 列印藥物諮詢  頁首

RESPONSE

The Micromedex Efficacy, Strength of Evidence and Strength of Recommendation definitions are outlined below:

Table 1. Strength Of Recommendation

Class I	Recommended	The given test or treatment has been proven to be useful, and should be performed or administered.
Class IIa	Recommended, In Most Cases	The given test, or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, In Some Cases	The given test, or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test, or treatment is not useful, and should be avoided.
Class Indeterminate	Evidence Inconclusive	

Table 2. Strength Of Evidence

Category A	Category A evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.
Category B	Category B evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).
Category C	Category C evidence is based on data derived from: Expert opinion or consensus, case reports or case series.
No Evidence	

Therapeutic Uses

2. 考量問題：使用抗凝血藥物是否可顯著降低中風危險？

Atrial fibrillation - Thromboembolic disorder: Prophylaxis

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

Strength of Evidence: Adult, Category A

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

Evidence (Elderly)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [15]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [15].

4) Elderly

a) Adjusted-dose warfarin reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and other clinically significant arterial embolism compared with aspirin 75 mg/day, among patients 75 years or older with chronic atrial fibrillation or atrial flutter, with no significant difference on major extracranial hemorrhage (BAFTA; N=973) [15].

Summary :
療效與出血風險

詳細說明的建議有...

檢視
資訊來源

Evidence (Elderly)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [15]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [15].

References

[15] Mant J, Hobbs R, Fletcher K, et al: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493-503.

PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

關閉

Adverse Reactions

3.考量問題：使用抗凝血藥物可能的副作用？

主頁	藥物 相互作用	IV 相容性	藥物 鑒定	藥物 比較	CareNotes®	NeoFax® / Pediatrics	其他工具 ▼
----	------------	--------	----------	----------	------------	----------------------	--------

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

REMS

Drug Interactions (single)

IV Compatibility (single)

Pregnancy & Lactation

Monitoring

Do Not Confuse

Adverse Effects

請參閱 '簡要解答' 瞭解綜述結果。

- Cardiovascular Effects
- Dermatologic Effects
- Endocrine/Metabolic Effects
- Gastrointestinal Effects
- Hematologic Effects**
- Hepatic Effects
- Immunologic Effects
- Musculoskeletal Effects
- Neurologic Effects
- Ophthalmic Effects
- Renal Effects
- Reproductive Effects
- Respiratory Effects
- Other

Cardiovascular Effects

Warfarin Sodium

Cholesterol embolus syndrome

Gangrenous disorder

Hemopericardium

Vasculitis

Cholesterol embolus syndrome

a) Summary

1) Systemic atheroemboli and cholesterol microemboli effecting solid organs and extremities, ranging from local necrosis to fatal cases, have occurred during warfarin therapy. Patients may present with

列印

Hematologic Effects

Warfarin Sodium

Anemia

Bleeding

Blood coagulation disorder

Eosinophilia

Hemolytic anemia

Hemorrhage

毒理學

Farmac

- Martindale

- RED Book Online

Product Lookup - Tox & Drug

消費者藥物資訊

Adverse Reactions

Hemorrhage

出血的危險因子

c) Summary

1) Risk factors for major or fatal bleeding in patients taking warfarin sodium include a higher starting INR, age 65 years or older, variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs, and long duration of warfarin therapy [116]. Other risk factors for a major bleed occurring during warfarin anticoagulation are comorbid conditions, atrial fibrillation, and the first 90 days of warfarin therapy [123][124][125]. Regular monitoring of INR should be performed on all patients. More frequent monitoring, careful dose adjustment, and a shorter duration of therapy may be warranted in patients at high risk for bleeding [116].

b) Prevention and Management

- 1) Perform regular (ie, generally every 1 to 4 weeks) INR monitoring in all treated patients [116]
- 2) Consider more frequent INR monitoring, careful dose titration to desired INR, and shortest possible therapy duration in high-risk patients [116]
- 3) Monitor INR more frequently with treatment initiation, dose adjustment, or withdrawal of other drugs (including botanicals) [116]
- 4) Determine INR immediately before any dental or surgical procedure [116]
- 5) Adjust the dose to maintain INR on the low end of the therapeutic range to continue anticoagulation in patients undergoing minimally invasive procedures [116]
- 6) Do not routinely base vitamin K antagonist (ie, warfarin) therapy interruption solely on clinical prediction rules for bleeding [3].
- 7) If the timeline for anticoagulant reversal is more than 24 hours, interrupt therapy. Oral or parenteral vitamin K may be administered if necessary [116] based on INR [147]
- 8) If expedited (ie, within 1 to 24 hours), oral or parenteral vitamin K(1) may be administered if necessary [116] based on INR [147]
- 9) If emergent (ie, within less than 1 hour), consider high-dose vitamin K. Consider high-dose concentrates (eg, 4-factor prothrombin complex concentrate, 3-factor prothrombin complex concentrate, activated prothrombin complex concentrate, recombinant factor VIIa, or fresh frozen plasma) [116][147]
- 10) The following are evidence-based guidelines from the American College of Chest Physicians for managing elevated INR or bleeding in patients on vitamin K antagonist (ie, warfarin) therapy:
 - a) INR between 4.5 and 10 with no evidence of bleeding:
 - 1) Routine use of vitamin K is not recommended [3].
 - b) INR greater than 10 with no evidence of bleeding:
 - 1) Administer oral vitamin K [3].
 - c) Vitamin K antagonist-associated major bleeding:
 - 1) Instead of plasma use, achieve rapid anticoagulation reversal with 4-factor prothrombin complex concentrate. Coadminister with vitamin K 5 to 10 mg via slow IV injection rather than attempting reversal with coagulation factor alone [3].

預防與管理： 針對不良反應之處理建議

Monitoring

5. 考量問題：使用抗凝血藥物須監測的項目/頻率？

Dosing/Administration

[Adult Dosing](#)[Pediatric Dosing](#)[FDA Uses](#)[Non-FDA Uses](#)[Dose Adjustments](#)[Administration](#)[Comparative Efficacy](#)[Place In Therapy](#)

Medication Safety

[Contraindications](#)[Precautions](#)[Adverse Effects](#)[Black Box Warning](#)

達到穩定狀態後的
建議監測頻率

[Pregnancy & Lactation](#)[Monitoring](#)

Medication Safety

Monitoring

請參閱 [簡要解答](#) 瞭解綜述結果。

[檢視完整文件](#)[列印](#)

監測項目與 監測頻率

A) Warfarin Sodium

1) Therapeutic

a) Laboratory Parameters

1) INR

a) Monitor INR daily following the initial warfarin dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks. Perform additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly. patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer) [2].

b) Monitor INR up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing. Evaluate the INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines) [1]

In general, the recommended target INR is 2.5 (range, 2 to 3) in adults and pediatric patients in most indications [112][1], except in the following situations:

Target INR is 3 (range 2.5 to 3.5):

相關結果

[毒理學](#)[疾病](#)[Drug Consults](#)[eMC SmPC \(UK\)](#)[Index Nominum](#)[IT- Dialogo Sui Farmaci](#)[Martindale](#)[PDR®](#)[Product Lookup - Martindale](#)[Product Lookup - RED Book Online](#)[Product Lookup - Tox & Drug](#)[消費者藥物資訊](#)

Patient Handouts

6. 考量問題：如何進行用藥指導？

Precautions	Tablet Take your medicine as directed. Your dose may need to be changed several times to find what works best for you. This medicine should come with a Medication Guide. Ask your pharmacist for a copy if you do not have one. Missed dose: Take a dose as soon as you remember. If it is almost time for your next dose, wait until then and take a regular dose. Do not take extra medicine to make up for a missed dose. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. <u>Drugs and Foods to Avoid:</u> Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products. Many medicines and foods affect how warfarin works and affect your PT/INR results. Tell your doctor before you start or stop any medicine, especially the following: <div><p>Another blood thinner, including apixaban, cilostazol, clopidogrel, dabigatran, dipyridamole, heparin, prasugrel, rivaroxaban, ticlopidine NSAID pain or arthritis medicine, including aspirin, celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, ketoprofen, ketorolac, naproxen, oxaprozin, piroxicam, sulindac (Check labels for over-the-counter medicines to find out if they contain an NSAID.) SSRI medicine (often treats depression or anxiety), including citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone Ginkgo, echinacea, or St John's wort</p></div>
Adverse Effects	
Black Box Warning	
REMS	
Drug Interactions (single)	
IV Compatibility (single)	
Pregnancy & Lactation	
Monitoring	
Do Not Confuse	
Mechanism of Action	
Mechanism of Action	
Pharmacokinetics	
Pharmacokinetics	
Patient Education	
Medication Counseling	
Patient Handouts	
Toxicology	
Clinical Effects	

搭配專業術語查詢

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes

NeoFax® /
Pediatrics

其他工具 ▼

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

Drugs that treat headache



Drugs that treat **headache**

Drugs that treat **headaches**

Drugs That Treat Headache

顯示： Effective (7) | Evidence Favors Efficacy (31) | Evidence is Inconclusive (2) | Ineffective (0) | Not Rated (0)

Displaying 40 results for "Drugs That Treat Headache"

將檢索結果，依證據等級分類

▼ Effective (7 results)

藥物名稱	Indication	年齡組別
Aspirin	Headache	Adult, Pediatric
Caffeine	Headache; Adjunct	Adult
Dihydroergotamine Mesylate	Cluster headache	Adult
Galcanezumab-gnlm	Episodic cluster headache	Adult
Ibuprofen	Headache	
Naproxen Sodium	Headache	Adult, Pediatric
Sumatriptan Succinate	Cluster headache	Adult

點擊藥品名稱，可進入藥品資訊

► Evidence Favors Efficacy (31 results)

► Evidence is Inconclusive (2 results)



工具好幫手

主頁

藥物
相互作用

IV 相容性

藥物
鑒定


藥物
比較

CareNotes

NeoFax® /
Pediatrics

其他工具 ▼

藥物相互作用



藥物相互作用

在搜尋欄位鍵入藥物名稱（品牌或學名）。選擇藥物並按一下 （新增）按鈕。

輸入搜尋詞

保健食品：
歐越莓/
山桑子/
覆盆子

相符的藥

Bilberry
Bilberry (Bilberry Extract)
Bilberry (Bilberry/Vitamin A/Vitamin E...
Bilberry (Homeopathic Substance)
Bilberry (Whortleberry)
Bilberry Extra Strength
Bilberry Extract
Bilberry Extract (Beta Carotene/Bilber...
Bilberry Extract (Bilberry Extract/Bio...
Bilberry Extract (Bilberry)
Bilberry Extract/Bioflavonoid/Querceti...

要檢查的藥物：

Bilberry
Ibuprofen
Warfarin

添加過敏

日常用藥：
止痛藥

治療用藥：
AF, 高血壓


添加過敏

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

新增過敏症狀。

在搜尋欄位中鍵入過敏症狀。選擇過敏症狀並按一下  (新增) 按鈕。
按一下「更新」將您的選擇加入至「藥物相互作用」中「要檢查的藥物」表單。

輸入過敏症狀:

asp

相符的過敏症狀: (7)

ASPARAGINASE
ASPARAGINE
ASPARAGUS
ASPARTIC ACID
ASPERGILLUS FUMIGATUS
ASPIRIN INTOLERANCE
ASPIRIN

要檢查的過敏症狀:

ASPIRIN
SEAFOOD



取消

更新

選擇藥物並按一下  (新增) 按鈕。

要檢查的藥物:

添加過敏

Bilberry
Ibuprofen
Warfarin
ASPIRIN*
SEAFOOD*



Bilberry Extra Strength
Bilberry Extract
Bilberry Extract (Beta Carotene/Bilber...
Bilberry Extract (Bilberry Extract/Bio...
Bilberry Extract (Bilberry)
Bilberry Extract/Bioflavonoid/Querceti...

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

Drug Interaction Results

← 修改相互作用

細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物-藥物 (2) | 複方 (0) | 過敏症狀 (1) | 食物 (12) | 乙醇 (1) | 實驗室 (1) | 抽煙 (1) | 懷孕 (2) | 哺乳期 (2)

Drug-Drug 相互作用 (2)

藥物：

IBUPROFEN -- WARFARIN SODIUM

BILBERRY -- WARFARIN SODIUM

嚴重性：



Major



Moderate

文件：

Fair

Fair

綜述：

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

複方 (未找到)

嚴重性
等級不同

Drug-過敏症狀 相互作用 (1)

藥物：

IBUPROFEN -- ASPIRIN

嚴重性：



Unknown

Warfarin分別和
Ibuprofen、歐越莓
併用皆會增加出血風險

Drug-食物 相互作用 (12)



定義

嚴重性：



禁忌

禁止同時使用這些藥物。



嚴重

這種相互作用可能危及生命和/或需要醫療干預以儘量減少或避免嚴重的不良影響。



中等

這種相互作用可能導致加重患者的病情和/或需要在治療中發生改變。



較弱

這種相互作用將限制臨床效果。表現可能包括增加副作用的頻率或嚴重程度，但一般不需要在治療中發生重大改變。



未知

未知。

INTERACTION DETAIL

Warning:

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

Clinical Management:

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

Onset:

Not Specified

INTERACTION DETAIL

Major

Documentation:

Fair

Probable Mechanism:

additive effect on hemostasis

Summary:

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

列印  關閉 

細化方式：藥物：All

嚴重性：2 (Selected)

文件：All

類型：All

跳轉到：藥物-藥物 (1) | 食物 (2) | 抽煙 (1) | 哺乳期 (1)

Drug-Drug 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
IBUPROFEN – WARFARIN SODIUM	 Major	Fair	Concurrent use of All NSAIDs may result in

Drug-食物 相互作用 (2)

藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	 Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	 Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

Drug-抽煙 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	 Major	Fair	Concurrent use of CYP1A2 SUBSTRATES and TOBACCO may result in decreased exposure of CYP1A2 substrates.

Drug-哺乳期 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
IBUPROFEN	 Major	Unknown	Infant risk cannot be ruled out: Available evidence and/ or expert consensus is inconclusive or is inadequate for determining infant risk when Ibuprofen is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Ibuprofen during breast-feeding.

選中/取消選中以細化嚴重性設定。

全部選中 | 全部不選

- ☒ Contraindicated
- ☒ Major
- ☐ Moderate
- ☐ Minor
- ☐ Unknown

取消

更新

定義

嚴重性：	 禁忌	 嚴重	 中等	 較弱	 未知
文件：	卓越	良好	一般	未知	

Ask Watson

多個藥物的IV相容性

IBM Micromedex®

[My Subscription](#) | [Gateway](#) | [Training Center](#) | [Help](#) | [Download Center](#) | [Logout](#)

Search Micromedex



[Home](#)

[Drug Interactions](#)

[IV Compatibility](#)

[Drug ID](#)

[Drug Comparison](#)

[CareNotes](#)

[NeoFax / Pediatrics](#)

[Other Tools ▼](#)

IV Compatibility

Type the drug name (brand or generic) in the search field. Select the drug and click the (x) button.

Enter search term:

Matching drug names: (2)

Palifermin
Palonosetron hydrochloride

Drugs to check:

Lorazepam
Palonosetron hydrochloride



Clear

Submit

適用於
焦慮狀態

化療用藥

Powered by Trissel's™ 2 Clinical Pharmaceuticals Database (Parenteral Compatibility).

IV Index contains the Confidential Information of BAXTER HEALTHCARE CORPORATION. Use of IV Index or information which it contains by anyone other than an expressed licensee is strictly prohibited.

多個藥物的IV相容性

IV 相容性

Add at least one drug and press View Compatibility

Drugs (1668)

適用於
焦慮狀態



Select Drug(s) to view Drug-Drug IV Compatibility



Lorazepam ×

Palonosetron hydrochloride ×

化療用藥

Solutions (257) *optional



Select Solution(s) to view Drug-Solution IV Compatibility



Clear All

View Compatibility



輸入至少一種藥品



需要時輸入溶液

NOTE: IV Compatibility for Drug - Drug Compatibility is displayed in drug pairs

由 Trissel's™ 2 Clinical Pharmaceuticals Database (Parenteral Compatibility). 支援。

多個藥物的IV相容性



IV 相容性結果 ◀ 修改相容性

Key :     

Preparation and Storage

Click to view Product and Storage Information

Drugs

-  Lorazepam
-  Palonosetron hydrochloride

Filter Results

☒ 全部選中 | ☐ 全部不選

Drugs

- ☒ Lorazepam
- ☒ Palonosetron hydrochloride

取消 更新

Tip: To see additional information on TPN/TNA compatibility, select a single drug from the list and choose Update.

Drug-Solution

Drug-Drug: Y-Site

Drug-Drug: Admixture

Drug-Drug: Syringe

相容性 :

All

Y-Site Results Summary (View Compatibility Details)

Status

Lorazepam - Palonosetron hydrochloride



相容

單一藥物的IV相容性

IV 相容性結果

[修改相容性](#)Key :     

相容性 :

All

Preparation and Storage

Click to view Product and Storage Information

Drugs

 Lorazepam Palonosetron hydrochloride

Filter Results

☒ 全部選中 | ☒ 全部不選

Drugs

☒ Lorazepam☐ Palonosetron hydrochloride[取消](#) [更新](#)

Drug-Solution

Y-Site

Admixture

Syringe

TPN/TNA

Y-Site Results Summary (View Compatibility Details)

Status

Acetaminophen



相容

Acyclovir sodium



相容

Alatrofloxacin mesylate



相容

Albumin Human



相容

Aldesleukin



不相容

Alemtuzumab



相容

Alfentanil hydrochloride



相容

藥物鑒定_用印碼查詢

IBM Micromedex®

[My Subscription](#) | [Gateway](#) | [Training Center](#) | [Help](#) | [Download Center](#) | [Logout](#)

Search Micromedex



[Home](#)

[Drug Interactions](#)

[IV Compatibility](#)

[Drug ID](#)

[Drug Comparison](#)

[CareNotes](#)

[NeoFax / Pediatrics](#)

[Other Tools ▼](#)

Drug Identification

Search: by Imprint Code | [No Imprint Code? Click here to search by Description ▶](#)

Side 1: ☒ Partial Imprint

Side 2: ☒ Partial Imprint


[Clear](#)

[Search](#)

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物鑒定

IBM Micromedex®

[My Subscription](#) | [Gateway](#) | [Training Center](#) | [Help](#) | [Download Center](#) | [Logout](#) 

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

Drug Identification Results

[◀ Modify Identification](#)[Search Images ▶](#) [Print](#)

6 Matches for: "mrk, 7"

Sort all Results by: [Imprint ▼](#)

6 Drug Matches for 'M'

1 - 6 (of 6 matching drugs) [◀ First](#) [◀ Previous](#) | [Next ▶](#) [Last ▶▶](#)Display: [ALL](#) | [0-9](#) | [A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | **M** | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

Imprint ▼	Drug Name	Manufacturer	Availability	AAPCC	Poisindex Managements
MRK 711 Singulair	Singulair	Merck Sharp & Dohme	United States	201078	MONTELUKAST
MRK 717 HYZAAR	Hyzaar 50-12.5	Merck Sharp & Dohme	United States	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
MRK 747 HYZAAR	Hyzaar 100-25	Merck Sharp & Dohme	United States	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
Mrk; 717	Hyzaar	Merck Frosst	Canada	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
Mrk; 74; Vioxx	Vioxx	Merck Frosst	Canada	201065	COX-2 INHIBITORS
Mrk; 74; Vioxx	Vioxx	Merck & Company	United States	201065	COX-2 INHIBITORS

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物鑒定

DRUG INFORMATION

Tox & Drug: [Hyzaar 100-25 ▶](#)

Martindale: [Hyzaar 100-25 ▶](#)

DRUG NAME: HYZAAR 100-25

INGREDIENTS: HYDROCHLOROTHIAZIDE -- 25 MG
LOSARTAN -- 100 MG

RELATED DOCUMENTS: POISINDEX MANagements - ANGIOTENSIN II ANTAGONISTS
POISINDEX MANagements - DIURETICS
DRUGDEX EVALUATIONS - LOSARTAN
DRUGDEX EVALUATIONS - HYDROCHLOROTHIAZIDE

COLOR: LIGHT YELLOW

SHAPE: TEARDROP-SHAPE

IMPRINT: HYZAAR, MRK 747

FORM: ORAL TABLET

AVAILABLE-CONTAINER-SIZE: BOTTLE OF 1000
, BOTTLE OF 90, STRIP OF 100, BOTTLE OF 4000
, BOTTLE OF 30

AAPCC CODE: 310109 - ANGIOTENSIN
RECEPTOR BLOCKER IN COMBINATION WITH
DIURETIC

NDC: 00006-0747-
00006-0747-
00006-0747-
00006-0747-
00006-0747-

EXCIPIENTS: D&C
LAKE; HYDROXY
; HYPROMELLOS
; MAGNESIUM ST
CELLULOSE; PR

REGULATORY S

AVAILABILITY: U

PRODUCT ID 572

藥物資訊

可用容器大小: BOTTLE OF 1000, BOTTLE OF 90
, STRIP OF 100, BOTTLE OF 4000, BOTTLE OF 30

AAPCC 代碼: 310109 - ANGIOTENSIN RECEPTOR
BLOCKER IN COMBINATION WITH DIURETIC

輔料: D&C YELLOW NO. 10 ALUMINUM LAKE
; HYDROXYPROPYL CELLULOSE
; HYPROMELLOSE; LACTOSE, HYDROUS
; MAGNESIUM STEARATE; MICROCRYSTALLINE
CELLULOSE; PREGELATINIZED STARCH

監管狀態: RX

可用性: UNITED STATES

產品 ID 5724722

聯絡資訊: MERCK SHARP & DOHME



No Image Available

列印 關閉

藥物鑒定_用外觀查詢



[Home](#)

[Drug Interactions](#)

[IV Compatibility](#)

[Drug ID](#)

[Drug Comparison](#)

[CareNotes](#)

[NeoFax / Pediatrics](#)

[Other Tools ▾](#)

Drug Identification

Search: by Description [Click here to search by Imprint Code ▾](#)

- | | | | |
|---------------------------------|--|---------------------------------|------------------------------------|
| <input type="checkbox"/> Black | <input type="checkbox"/> Blue | <input type="checkbox"/> Brown | <input type="checkbox"/> Clear |
| <input type="checkbox"/> Gold | <input type="checkbox"/> Gray | <input type="checkbox"/> Green | <input type="checkbox"/> Off-White |
| <input type="checkbox"/> Orange | <input checked="" type="checkbox"/> Pink | <input type="checkbox"/> Purple | <input type="checkbox"/> Red |
| <input type="checkbox"/> Tan | <input type="checkbox"/> White | <input type="checkbox"/> Yellow | |

Shape:

Pattern:

☒ Show Images with results

[Clear](#)

[Search](#)

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

5 Matches for: "Egg-shape, All Patterns, Pink"

Sort all Results by:

1 Drug Match for 'A'

1 - 1 (of 1 matching drugs) [◀First](#) [◀Previous](#) | [Next](#) [▶Last](#)▶

Display: [ALL](#) | [0-9](#) | [A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

[Hide Images](#)

Image (US)

Imprint ▾

Drug Name



AMOXIL 125

Amoxil

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物比較

IBM Micromedex®

[My Subscription](#) | [Gateway](#) | [Training Center](#) | [Help](#) | [Download Center](#) | [Logout](#)

Search Micromedex



Home

Drug
Interactions

IV Compatibility

Drug ID

Drug
Comparison

CareNotes

NeoFax / Pediatrics

Other Tools ▼

Drug Comparison

Type the drug name (brand or generic) in the search field. Select the drug and click the ➤ (Add) button.

Enter search term:

warf

Matching drug names: (2)

Warfarin Na
Warfarin Sodium

Drugs to check:

Dabigatran Etexilate Mesylate
Rivaroxaban
Warfarin Sodium

Clear

Submit

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物比較(適應症)_證據等級

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

Drug Comparison Results

◀ Modify Comparison

Display in Column 1

Warfarin Sodium ▼

Display in Column 2

Dabigatran Etexilate Mesylate ▼

Update

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

FDA-Labeled Indications

View Detailed information in DRUGDEX ▶

▶ Atrial fibrillation - Thromboembolic disorder

FDA Approval:

- Adult, yes
- Pediatric, no

Efficacy:

- Adult, Effective

Strength of Recommendation:

- Adult, [Class I](#)

Strength of Evidence:

- Adult, [Category A](#)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Approval:

- Adult, yes
- Pediatric, no

FDA-Labeled Indications

View Detailed information in DRUGDEX ▶

▶ Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Approval:

- Adult, yes
- Pediatric, no

Efficacy:

- Adult, Effective

Strength of Recommendation:

- Adult, [Class IIa](#)

Strength of Evidence:

- Adult, [Category B](#)

Deep venous thrombosis, Following parenteral therapy

FDA Approval:

- Adult, yes
- Pediatric, no

藥物比較(不良反應)_一般/嚴重

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

Drug Comparison Results [◀ Modify Comparison](#)

Display in Column 1

Warfarin Sodium ▼

Display in Column 2

Dabigatran Etexilate Mesylate ▼

[Update](#)

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single Action/Pharmacokinetics\)](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#) | **[Adverse Effects](#)** | [Name Info](#) | [Mechanism of](#)

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Dermatologic:** Alopecia

Serious

- **Cardiovascular:** Cholesterol embolus syndrome, Tissue necrosis (Less than 0.1%)
- **Dermatologic:** Calciphylaxis, Tissue necrosis (Less than 0.1%)
- **Hematologic:** Hemorrhage, Hemorrhage
- **Immunologic:** Hypersensitivity reaction
- **Musculoskeletal:** Compartment syndrome
- **Neurologic:** Intracranial hemorrhage

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Gastrointestinal:** Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5%), Gastrointestinal hemorrhage (DVT and pulmonary embolism, 0.7% to 3.1%; nonvalvular atrial fibrillation, 6.1%), Gastrointestinal ulcer, Indigestion (DVT and pulmonary embolism, 4.1% to 7.5%)
- **Hematologic:** Hemorrhage (DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; nonvalvular atrial fibrillation, 16.6%)

Serious

- **Cardiovascular:** Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7%)
- **Gastrointestinal:** Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6%)
- **Hematologic:** Hemorrhage, Major (DVT and pulmonary embolism, 0.3% to 2%; nonvalvular atrial fibrillation, 3.3%), Thrombosis
- **Immunologic:** Anaphylaxis
- **Neurologic:** Epidural hematoma, Intracranial hemorrhage (Nonvalvular atria

藥物比較-切換另一藥物

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

Drug Comparison Results ◀ Modify Comparison



Display in Column 1

Warfarin Sodium

Display in Column 2

Dabigatran Etexilate Mesylate
Dabigatran Etexilate Mesylate
Rivaroxaban
Warfarin Sodium

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Dermatologic:** Alopecia

Serious

- **Cardiovascular:** Cholesterol embolus syndrome, Tissue necrosis (Less than 0.1%)
- **Dermatologic:** Calciphylaxis, Tissue necrosis (Less than 0.1%)
- **Hematologic:** Hemorrhage, Hemorrhage
- **Immunologic:** Hypersensitivity reaction
- **Musculoskeletal:** Compartment syndrome

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Gastrointestinal:** Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5%), Gastrointestinal hemorrhage (DVT and pulmonary embolism, 0.7% to 3.1%; nonvalvular atrial fibrillation, 6.1%), Gastrointestinal ulcer, Indigestion (DVT and pulmonary embolism, 4.1% to 7.5%)
- **Hematologic:** Hemorrhage (DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; nonvalvular atrial fibrillation, 16.6%)

Serious

- **Cardiovascular:** Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7%)
- **Gastrointestinal:** Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6%)
- **Hematologic:** Hemorrhage, Major (DVT and pulmonary embolism, 0.3% to 2%; nonvalvular atrial fibrillation, 3.3%), Thrombosis
- **Immunologic:** Anaphylaxis


Ask Watson 有問題，問華生！

IBM Micromedex 為何需要華生?



資料太多眼昏花

IBM Micromedex 為何需要華生?



華生相助精準查

怎麼找華生？

IBM Micromedex®

[我的訂閱](#) | [開進](#) | [Training Center](#) | [說明](#) | [下載中心](#) | [登出](#)

[主頁](#)
[藥物相互作用](#)
[IV 相容性](#)
[藥物鑒定](#)
[藥物比較](#)
[CareNotes](#)
[NeoFax / Pediatrics](#)
[其他工具 ▾](#)

[全部](#)
[藥物](#)
[疾病](#)
[毒理學](#)

[Learn more ?](#)

最新消息

- Toxicology & Product Search Updates
- First Lyrica(R) Generics Approved
- Recarbrio(TM) for cUTI and cIAI
- Micromedex Updates on July 24

[Read Top News](#)

支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide


[Support Request](#)

資源


- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

[Download Mobile Apps](#)

怎麼問華生？



點按華生即顯示
問題範例



怎麼問華生？

Ask Watson

Search Micromedex drug information

Type a quick question...



Learn more ?

點按Learn more即顯示
智能檢索說明

About IBM Micromedex with Watson

Conversational Search:

Micromedex with Watson uses cognitive computing in the IBM cloud to gather search intent through conversation, provide specific clinical answers, and guide clinicians to relevant evidence.

How Micromedex with Watson Works:

Ask questions in a natural way, the way clinicians ask clinicians. The more specific the question, the more specific the answer. Examples:

- What's the adult dose of lisinopril for hypertension?
- What are approved uses for pristiq?
- What are the adverse effects of digoxin?
- Can cefazolin be given IV push?
- How fast can Daptomycin be given?

Micromedex with Watson Understands:

Watson is in medical residency and can answer many drug information questions. The system learns from interaction with users and will be able to answer more sophisticated questions over time. For now, answers are limited to:

- Drug Information (e.g. Drug Classes, Dosing, Administration, Medication Safety, Mechanism of Action, Pharmacokinetics, About)
- Drug Interactions
- IV Compatibility

關閉 X

怎麼問華生？

像同事之間一樣問問題

華生現在知道：

藥物資訊 藥物分類、劑量、給藥、
藥物安全性、作用、藥物
動力學、關於機制
藥物交互作用 單一藥物
IV相容性 Solution, Y site,
Admixture, Syringe,
TPN / TNA

華生還不知道：

NeoFax / Pediatrics, Toxicology,
Disease, Lab, Alternative
Medicine, Reproductive Risk
第三方內容（例如Martindale, Index
Nominum）

About IBM Micromedex with Watson

Conversational Search:

Micromedex with Watson uses cognitive computing in the IBM cloud to gather search intent through conversation, provide specific clinical answers, and guide clinicians to relevant evidence.

How Micromedex with Watson Works:

Ask questions in a natural way, the way clinicians ask clinicians. The more specific the question, the more specific the answer. Examples:

- What's the adult dose of lisinopril for hypertension?
- What are approved uses for pristiq?
- What are the adverse effects of digoxin?
- Can cefazolin be given IV push?
- How fast can Daptomycin be given?

Micromedex with Watson Understands:

Watson is in medical residency and can answer many drug information questions. The system learns from interaction with users and will be able to answer more sophisticated questions over time. For now, answers are limited to:

- Drug Information (e.g. Drug Classes, Dosing, Administration, Medication Safety, Mechanism of Action, Pharmacokinetics, About)
- Drug Interactions
- IV Compatibility

關閉 X

Demo Slides

對話式檢索範例


就像跟你的同事問問題一樣，

對話將提供簡要解答內容、簡要解答連結、深入解答連結

- Dosing and adjustments 劑量與調整
- Adverse effects 不良反應
- Contraindications 禁忌症
- Precautions 注意事項
- Administration 管理
- More 更多

提問範例：

“What’s the adult dose of warfarin for Atrial fibrillation?”



對話式檢索介面

智能過濾器

簡要解答內容

簡要解答連結

深入解答連結

意見回饋

對話檢索框

Warfarin ... x Atrial fibr... x adult x Clear

Here is the adult dosing for warfarin sodium:

Atrial fibrillation - Thromboembolic disorder



- Initial, 2 to 5 mg orally once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg orally once a day
- Following an ischemic stroke or transient ischemic attack, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosing)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg orally once a day

Quick Answers Adult Dosing for Warfarin Sodium

In-Depth Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...

IBM Micromedex Watson Assistant

Warfarin... x Atrial fibr... x adult x Clear

Can I give with food?
What patient monitoring is needed?

What's the adult dose of warfarin for Atrial fibrillation

Here is the adult dosing for warfarin sodium:

Atrial fibrillation - Thromboembolic disorder



- Initial, 2 to 5 mg orally once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg orally once a day
- Following an ischemic stroke or transient ischemic attack, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosing)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg orally once a day

Quick Answers Adult Dosing for Warfarin Sodium

In-Depth Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...


對話式檢索範例

無論是手滑打錯、語意不明、病名縮寫都沒關係，華生會再次確認，提供你正確答案

提問範例：
adult warfarin AF

Would you like to see the warfarin sodium dosing for atrial fibrillation?

yes




對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

“Are dose adjustment needed?”



The screenshot shows the Watson Assistant interface. At the top, there's a header "Watson Assistant" with a close button. Below it, a search bar contains the text "Warfarin ...", "Atrial fibr...", and "adult", with a "Clear" button. A dark notification bubble says "Are dose adjustment needed". The main content area displays the text "Here are the warfarin sodium dose adjustments:" followed by a bulleted list of clinical guidelines. At the bottom, there's a feedback question "Was this helpful?" with thumbs up/down icons and a text input field labeled "Type something..."



Watson Assistant

Warfarin ... x Atrial fibr... x adult x Clear

Are dose adjustment needed

Here are the warfarin sodium dose adjustments:

- Renal impairment: No adjustment necessary
- Geriatric: Consider using lower initial and maintenance dosage
- INR; single out of range value, below or above the therapeutic INR by 0.5 or less, continue current warfarin dose and test INR within 1 to 2 weeks
- discontinuing therapy: abrupt discontinuation is suggested rather than gradual tapering of the dose (ACCP guidelines)
- CYP2C9 and VKORC1 genetic variation: initial dose, based on genotype information
 - - expected doses range, CYP2C9 *1/*1: (VKORC1 GG, AG) 5 to 7 mg; (VKORC1 AA) 3 to 4 mg
 - - expected doses range, CYP2C9 *1/*2: (VKORC1 GG) 5 to 7 mg; (VKORC1 AG, AA) 3 to 4 mg
 - - expected doses range, CYP2C9 *1/*3: (VKORC1 GG, AG) 3 to 4 mg; (VKORC1 AA) 0.5 to 2 mg
 - - expected doses range, CYP2C9 *2/*2: (VKORC1 GG, AG) 3 to 4 mg; (VKORC1 AA) 0.5 to 2 mg
 - - expected doses range, CYP2C9 *2/*3: (VKORC1 GG) 3 to 4 mg; (VKORC1 AG, AA) 0.5 to 2 mg
 - - expected doses range, CYP2C9 *3/*3: (VKORC1 GG, AG, AA) 0.5 to 2 mg
- Pregnancy, mechanical valve: Warfarin to goal INR plus aspirin 75 mg to 100 mg/day during second and third trimesters; during first trimester, warfarin may be continued in patients who are achieving therapeutic INR with doses of 5

Was this helpful?  


Type something...

對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

“What patient monitoring is needed?”



The screenshot shows the Watson Assistant chat interface. At the top, there's a title bar "Watson Assistant" with standard window controls. Below it is a search bar containing three filters: "Warfarin...", "Atrial fibr...", and "adult", with a "Clear" button. The main chat area displays a user query in a bubble: "What patient monitoring is needed". Below the query, the assistant's response is shown, starting with "Here is the warfarin sodium monitoring information:". This is followed by a bulleted list of monitoring guidelines. At the bottom of the chat area, there's a feedback prompt "Was this helpful?" with thumbs up/down icons and a text input field labeled "Type something...".



Watson Assistant

Warfarin... Atrial fibr... adult Clear

What patient monitoring is needed

Here is the warfarin sodium monitoring information:

- INR: daily following the initial dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks; additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly; patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer)
- INR: up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing; evaluate INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines)
- INR: Immediately prior to any dental or surgical procedure
- INR (pediatric): More frequently to ensure target INR is achieved and maintained the low-dose prophylactic target INR is 1.7 (range 1.5 to 1.9)
- INR: More frequently in patients with high risk of bleeding, when starting or stopping other drugs, changing dosages of other drugs, and in patients with renal impairment
- INR (when administered with heparin): Sample at least 5 hours after the last IV bolus dose of heparin, 4 hours after stopping continuous IV heparin infusion, 24 hours after the last subcutaneous heparin injection

Was this helpful?  

Type something...

對話式檢索範例

如在前述問題下接續詢問前述藥物與特定藥物的交互作用，結果將提供連結引導您到藥物交互作用的頁面

提問範例：
“Are there interactions with TAMOXIFEN?”

Drug Interactions for Tamoxifen Citrate

Watson Assistant

Tamoxif... x Clear

Drug Interaction Results 修改相互作用

細化方式： Drug Tamoxifen Citrate 嚴重性： All 文件： All

跳轉到： Drug-Drug (111) | 過敏症狀 (0) | 食物 (0) | 乙醇 (0) | 實驗室 (0) | 抽煙 (0) | 懷孕 (1) | 哺乳 (1)

藥物：	嚴重性：	文件：
MESORIDAZINE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Excellent
WARFARIN [Systemic] -- TAMOXIFEN [Systemic]	Contraindicated	Good
ZIPRASIDONE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair
SAQUINAVIR -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair

Are there interactions with TAMOXIFEN

Here are the drug interactions for tamoxifen citrate:

[Drug Interactions for Tamoxifen Citrate](#)

對話式檢索範例

除單一藥物的交互作用清單外，亦可直接查詢多個藥物交互作用

提問範例：

“interactions among
bilberry Losartan
Warfarin ibuprofen?”

IBM Micromedex Watson Assistant

Drug Interaction Results

細化方式：藥物：All 嚴重性：All 文件：All 類型：All

跳轉到：藥物-藥物 (2) | 複方 (0) | 過敏症狀 (0) | 食物 (13) | 乙醇 (1) | 實驗室 (1) | 抽煙 (1) | 懷孕 (3) | 哺乳 (3)

Drug-Drug 相互作用 (2)

藥物：	嚴重性：	文件：	描述：
IBUPROFEN -- WARFARIN SODIUM	Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.
IBUPROFEN -- LOSARTAN POTASSIUM	Moderate	Excellent	Concurrent use of ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS and NSAIDS may result in renal dysfunction and/or increased blood pressure.

複方 (未找到)

Drug-過敏症狀 相互作用 (未找到)

Drug-食物 相互作用 (13)

藥物：	嚴重性：	文件：	描述：
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

Ibuprofen

Here are the drug interactions for ibuprofen, losartan potassium and warfarin sodium:


Drug Interactions

對話式檢索範例

若您提出新藥或新病患問題繼續發問，華生將為您重置問題情境並提供相關解答，您無須自行清除前述提問

提問範例：

“what drug treat gout?”



對話式檢索範例


若您提出新藥或新病患問題繼續發問，華生將為您重置問題情境並提供相關解答，或是追問細節以釐清問題，您無須自行清除前述提問

提問範例：

what are the drugs that treat AF

Is it for Adult or Pediatric?

adult



Q & A Thank You!

客戶服務中心

服務專線：02-7731-5800

服務傳真：02-8226-5022

客戶服務信箱：services@customer-support.com.tw

專人服務時間：週一～週五 9:00~17:30

系統服務時間：全年無休